10:39 AM EDT, 04/08/2025 (MT Newswires) -- IGC Pharma ( IGC ) said Tuesday it is expanding its phase 2 trial of IGC-AD1 in Alzheimer's disease by adding Butler Hospital's Memory and Aging Program in Providence, Rhode Island.

The site will help enroll participants for the study of IGC-AD1

potential in reducing agitation in Alzheimer's dementia, the company said. The research center is affiliated with the Warren Alpert Medical School of Brown University.

The trial is being conducted in the US and Canada, with a goal of enrolling 146 participants, IGC said.